Optimising dose-dense regimens for early breast cancer
Clifford Hudis takes a look at how dose-dense regimens, intended to increase efficacy by decreasing the time between doses, work and effect toxicity in early breast cancer, especially where targeted agents are added. Dose-dense regimens [more]